NHAS
Novo Holdings A/S Portfolio holdings
AUM $1.42B
1-Year Return
12.08%
This Quarter Return
-9.24%
1 Year Return
+12.08%
3 Year Return
+99.82%
5 Year Return
+98.46%
10 Year Return
+612.59%
AUM
$1.31B
AUM Growth
-$337M
(-20%)
Cap. Flow
-$148M
Cap. Flow
% of AUM
-11.26%
Top 10 Holdings %
Top 10 Hldgs %
74.12%
Holding
34
New
–
Increased
13
Reduced
4
Closed
3
Top Buys
| 1 |
CBLL
CeriBell, Inc. Common Stock
CBLL
|
+$10.6M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
+$10.6M |
| 3 |
Edgewise Therapeutics
EWTX
|
+$7.7M |
| 4 |
ArriVent BioPharma
AVBP
|
+$6.5M |
| 5 |
Vaxcyte
PCVX
|
+$6.23M |
Top Sells
| 1 |
TEM
Tempus AI, Inc. Class A Common Stock
TEM
|
+$138M |
| 2 |
Brookfield
BN
|
+$24.5M |
| 3 |
CRGX
CARGO Therapeutics
CRGX
|
+$24M |
| 4 |
Alibaba
BABA
|
+$10.6M |
| 5 |
Mersana Therapeutics
MRSN
|
+$6.08M |
Sector Composition
| 1 | Healthcare | 50.89% |
| 2 | Technology | 14.07% |
| 3 | Financials | 9.29% |
| 4 | Consumer Discretionary | 3.75% |
| 5 | Industrials | 0.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vanguard Total Stock Market ETF
VTI
$540B
| $285M | 21.71% |
1,038,550
| – | – |
|
|
2
Brookfield
BN
$104B
| $122M | 9.29% |
2,330,830
-468,000
| -17% | -$24.5M |
|
|
3
Edgewise Therapeutics
EWTX
$1.48B
| $118M | 8.95% |
5,350,000
+350,000
| +7% | +$7.7M |
|
4
ASML
ASML
$345B
| $110M | 8.36% |
165,836
| – | – |
|
5
Salesforce
CRM
$228B
| $73.2M | 5.57% |
272,801
-21,100
| -7% | -$5.66M |
|
6
Mirum Pharmaceuticals
MIRM
$3.71B
| $67.6M | 5.14% |
1,500,000
| – | – |
|
7
Insmed
INSM
$30.6B
| $55.3M | 4.21% |
724,666
| – | – |
|
8
Recursion Pharmaceuticals
RXRX
$2.11B
| $51.1M | 3.89% |
9,665,128
-449,505
| -4% | -$2.38M |
|
|
9
Alibaba
BABA
$387B
| $49.2M | 3.75% |
372,327
-80,000
| -18% | -$10.6M |
|
|
10
Crinetics Pharmaceuticals
CRNX
$3.21B
| $42.8M | 3.25% |
1,275,000
+314,785
| +33% | +$10.6M |
|
11
BioMarin Pharmaceuticals
BMRN
$10.4B
| $34.6M | 2.63% |
490,000
| – | – |
|
|
12
ArriVent BioPharma
AVBP
$738M
| $34.6M | 2.63% |
1,872,142
+351,515
| +23% | +$6.5M |
|
|
13
Vaxcyte
PCVX
$4.05B
| $34.6M | 2.63% |
915,000
+165,000
| +22% | +$6.23M |
|
14
Merus
MRUS
$5.06B
| $33.2M | 2.53% |
789,129
+39,129
| +5% | +$1.65M |
|
15
Viridian Therapeutics
VRDN
$1.52B
| $30.3M | 2.31% |
2,250,300
+300
| +0% | +$4.04K |
|
16
Pharvaris
PHVS
$1.53B
| $27.1M | 2.06% |
1,725,000
| – | – |
|
17
Amicus Therapeutics
FOLD
$2.47B
| $22.4M | 1.71% |
2,750,000
+250,000
| +10% | +$2.04M |
|
18
Celldex Therapeutics
CLDX
$1.63B
| $21.8M | 1.66% |
1,200,000
+200,000
| +20% | +$3.63M |
|
|
BPMC
19
DELISTED
Blueprint Medicines
BPMC
| $20.3M | 1.54% |
228,804
+53,804
| +31% | +$4.76M |
|
|
ZBIO
20
Zenas BioPharma, Inc. Common Stock
ZBIO
$768M
| $17.5M | 1.33% |
2,214,967
+614,967
| +38% | +$4.86M |
|
|
CBLL
21
CeriBell, Inc. Common Stock
CBLL
$428M
| $16.9M | 1.29% |
880,000
+551,191
| +168% | +$10.6M |
|
|
VERV
22
DELISTED
Verve Therapeutics
VERV
| $13.7M | 1.04% |
3,000,000
+600,000
| +25% | +$2.74M |
|
23
Rocket Pharmaceuticals
RCKT
$351M
| $7.34M | 0.56% |
1,100,000
| – | – |
|
24
4D Molecular Therapeutics
FDMT
$312M
| $6.3M | 0.48% |
1,950,000
+450,000
| +30% | +$1.45M |
|
25
Lexeo Therapeutics
LXEO
$281M
| $3.9M | 0.3% |
1,122,581
| – | – |
|